Immuno-PET for Clinical Theranostic Approaches

Abstract

Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.

Keywords: antibody; immuno-PET; molecular imaging.

Figure 1

Topic of research on Webofknowledge.com: “immuno-positron emission tomography (PET)”. This report reflects citations to source items indexed within Web of Science Core Collection.

Figure 2

Immuno-PET maximum-intensity-projection images recorded in five patients (one patient of each cohort, A to E) included in the optimization part of the first-in-human immuno-PET trial using anti-carcinoembryonic antigen CEA bispecific antibody and ⁶⁸Ga-labelled peptide in metastatic medullary thyroid carcinoma. Arrows showed foci considered as pathologic by immuno-PET. (This research was originally published in JNM. Immuno-PET using anti-CEA bispecific antibody and ⁶⁸Ga-labelled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pre-targeting parameters in a First-in Human trial. Bodet-Milin et al. J. Nucl. Med. 2016, 57, 1505–1511. © by the Society of Nuclear Medicine and Molecular Imaging, Inc., Reston, VA, USA).